Seaport Therapeutics, Inc. (SPTX) shareholders
Close on Nov 17, 2026Market cap $972.65MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| PureTech Health plc Joint filing with PureTech Health LLC (31.20%), PureTech LYT, Inc. (31.20%) | 16,685,013 | 31.20% | 13G (passive) | Jun 30, 2026 |
| ARCH Venture Fund XII, L.P. Joint filing with ARCH Venture Partners XII, L.P. (11.90%), ARCH Venture Partners XII, LLC (11.90%) and 4 more | 6,294,951 | 11.90% | 13D (active) | May 4, 2026 |
| General Atlantic (Lux) S.a r.l. Joint filing with General Atlantic, L.P. (11.50%), General Atlantic (SPV) GP, LLC (11.50%) and 11 more | 6,101,582 | 11.50% | 13D (active) | May 4, 2026 |
| Zohar Daphne | 5,225,497 | 9.10% | 13G (passive) | Jun 30, 2026 |
| Paul Steven M | 3,516,718 | 6.30% | 13G (passive) | Jun 30, 2026 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (5.50%) | 2,791,814 | 5.50% | 13G (passive) | May 6, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SPTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 6,294,951 | 11.76% | $136.60M | New | 12.42% |
| General Atlantic, L.P. | 6,101,582 | 11.40% | $132.53M | New | 4.56% |
| Sofinnova Investments, Inc. | 3,564,871 | 6.66% | $77.43M | New | 4.00% |
| Goldman Sachs Group Inc | 2,178,642 | 4.07% | $47.32M | New | 0.00% |
| Trv Gp Vi, LLC | 2,061,222 | 3.85% | $44.77M | New | 19.27% |
| Canada Pension Plan Investment Board | 1,975,791 | 3.69% | $42.91M | New | 0.02% |
| JPMorgan Chase & Co | 1,815,845 | 3.39% | $40.89M | New | 0.00% |
| Foresite Capital Management VI LLC | 1,779,521 | 3.32% | $38.65M | New | 6.02% |
| Price T Rowe Associates Inc /Md/ | 1,308,604 | 2.44% | $28.42M | New | 0.00% |
| FMR LLC | 1,185,100 | 2.21% | $25.74M | New | 0.00% |
| Bellevue Group AG | 1,100,000 | 2.05% | $23.89M | New | 0.50% |
| Siren, L.L.C. | 1,095,316 | 2.05% | $23.79M | New | 0.48% |
| Jennison Associates LLC | 1,079,669 | 2.02% | $23.45M | New | 0.01% |
| Ra Capital Management, L.P. | 700,000 | 1.31% | $15.20M | New | 0.13% |
| Vanguard Capital Management LLC | 599,217 | 1.12% | $13.01M | New | 0.00% |
| Woodline Partners LP | 586,345 | 1.10% | $12.74M | New | 0.04% |
| Braidwell LP | 500,000 | 0.93% | $10.86M | New | 0.40% |
| Perceptive Advisors LLC | 500,000 | 0.93% | $10.86M | New | 0.16% |
| Principal Financial Group Inc | 414,672 | 0.77% | $9.01M | New | 0.00% |
| abrdn plc | 310,355 | 0.58% | $6.74M | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 54 | 37M | 69.9% | 54 / 0 | 0 / 0 | 37M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SPTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| JPMorgan Small Cap Growth Fund | 840,931 | 1.57% | $18.27M | 0.70% | Jun 30, 2026 |
| PGIM Jennison Health Sciences Fund | 438,754 | 0.82% | $7.98M | 0.57% | May 29, 2026 |
| Vanguard Total Stock Market Index Fund | 426,371 | 0.80% | $9.26M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 299,319 | 0.56% | $6.50M | 0.05% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 271,499 | 0.51% | $5.90M | 0.35% | Jun 30, 2026 |
| Fidelity Blue Chip Growth Fund | 235,900 | 0.44% | $4.83M | 0.00% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 224,400 | 0.42% | $4.08M | 0.00% | May 31, 2026 |
| SmallCap Fund | 181,500 | 0.34% | $3.71M | 0.18% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 165,436 | 0.31% | $3.59M | 0.00% | Jun 30, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 107,880 | 0.20% | $1.96M | 0.15% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 62,296 | 0.12% | $1.13M | 0.00% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 55,900 | 0.10% | $1.02M | 0.00% | May 31, 2026 |
| Fidelity Blue Chip Growth K6 Fund | 48,109 | 0.09% | $984.31K | 0.00% | Jul 31, 2026 |
| Fidelity Series Blue Chip Growth Fund | 43,700 | 0.08% | $894.10K | 0.01% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 29,589 | 0.06% | $642.67K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daphne Zohar | Chief Executive Officer, Director | 1,094,001 | 2.04% | Nov 13, 2026 |
| Lana Gladstein | General Counsel | 33,515 | 0.06% | May 4, 2026 |
| Michael Cunyuan Chen | Chief Scientific Officer | 3,351 | 0.01% | May 4, 2026 |
| Lauren White | Chief Financial Officer | 6,702 | 0.01% | May 4, 2026 |
| Antony Loebel | Chief Medical Officer | 20,109 | 0.04% | May 4, 2026 |
| Denice Torres | Director | 18,406 | 0.03% | Nov 4, 2026 |
| Robert J. Hombach | Director | 13,000 | 0.02% | Jun 24, 2026 |
| General Atlantic (SP), L.P. | Director, 10% owner | – | – | May 6, 2026 |
| Gap Coinvestments Iii, Llc | Director, 10% owner | – | – | May 6, 2026 |
| General Atlantic, L.P. | Director, 10% owner | – | – | May 6, 2026 |
| GAP Coinvestments CDA, L.P. | Director, 10% owner | – | – | May 6, 2026 |
| Gap Coinvestments Iv, Llc | Director, 10% owner | – | – | May 6, 2026 |
| (Bermuda) L.P. GAP | Director, 10% owner | – | – | May 6, 2026 |
| General Atlantic Genpar (Bermuda), L.P. | Director, 10% owner | – | – | May 6, 2026 |
| General Atlantic Genpar, L.P. | Director, 10% owner | – | – | May 6, 2026 |
| GAP Coinvestments V, LLC | Director, 10% owner | – | – | May 6, 2026 |
| General Atlantic (SPV) GP, LLC | Director, 10% owner | 6,101,582 | 11.40% | May 6, 2026 |
| Atlantic GenPar (Lux) SCSp General | Director, 10% owner | 6,101,582 | 11.40% | May 6, 2026 |
| General Atlantic Partners (Lux), SCSp | Director, 10% owner | – | – | May 6, 2026 |
| General Atlantic Partners 100, L.P. | Director, 10% owner | – | – | May 6, 2026 |
| Atlantic (Lux) S.a r.l. General | Director, 10% owner | – | – | May 6, 2026 |
| James Healy | Director | 1,927,159 | 3.60% | May 4, 2026 |
| Sharon Mates | Director | – | – | May 4, 2026 |
| Steven M. Paul | Director | 863,031 | 1.61% | May 4, 2026 |
| David E. Wheadon | Director | – | – | May 4, 2026 |
| Sandra E. Peterson | Director | – | – | May 4, 2026 |
| Jason Pitts | Director | – | – | Apr 30, 2026 |
| Health plc PureTech | 10% owner | 13,038,493 | 24.36% | May 6, 2026 |
| PureTech LYT, Inc. | 10% owner | – | – | May 6, 2026 |
| Robert Nelsen | 10% owner | – | – | May 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daphne Zohar Chief Executive Officer, Director | Nov 10, 2026 | Gift | −100,000 | – | – | 1,094,001 |
| Denice Torres Director | Nov 3, 2026 | Buy | +5,000 | $19.86 | $99.32K | 5,000 |
| Robert J. Hombach Director | Jun 22, 2026 | Buy | +13,000 | $18.14 | $235.82K | 13,000 |
| Health plc PureTech 10% owner | May 4, 2026 | Conversion | +12,736,014 | – | – | 13,038,493 |
| Health plc PureTech 10% owner | May 4, 2026 | Conversion | +965,255 | – | – | 16,685,013 |
| Health plc PureTech 10% owner | May 4, 2026 | Conversion | +2,681,265 | – | – | 15,719,758 |
| Michael Cunyuan Chen Chief Scientific Officer | May 4, 2026 | Conversion | +3,351 | – | – | 3,351 |
| Lana Gladstein General Counsel | May 4, 2026 | Conversion | +33,515 | – | – | 33,515 |
| Antony Loebel Chief Medical Officer | May 4, 2026 | Conversion | +20,109 | – | – | 20,109 |
| Lauren White Chief Financial Officer | May 4, 2026 | Conversion | +6,702 | – | – | 6,702 |
| Steven M. Paul Director | May 4, 2026 | Conversion | +67,031 | – | – | 863,031 |
| ARCH Venture Partners XII, L.P. 10% owner | May 4, 2026 | Conversion | +2,513,686 | – | – | 2,513,686 |
| ARCH Venture Partners XII, L.P. 10% owner | May 4, 2026 | Conversion | +2,681,265 | – | – | 5,194,951 |
| ARCH Venture Partners XII, L.P. 10% owner | May 4, 2026 | Buy | +1,100,000 | $18.00 | $19.80M | 6,294,951 |
| James Healy Director | May 4, 2026 | Conversion | +1,927,159 | – | – | 1,927,159 |
| James Healy Director | May 4, 2026 | Conversion | +804,379 | – | – | 2,731,538 |
| Denice Torres Director | May 4, 2026 | Conversion | +13,406 | – | – | 13,406 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 6 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Seaport Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 58,886 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?